[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.148.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1985

How Should We Manage a Patient With Uveal Melanoma?

Arch Ophthalmol. 1985;103(7):910-911. doi:10.1001/archopht.1985.01050070036025
Abstract

For approximately 100 years, enucleation has been the standard treatment for uveal melanoma.1 It has been assumed that removing the cancer soon after diagnosis would prolong the patient's life. In the 1960s, the urgency to enucleate was suppressed somewhat by a report that up to 20% of eyes removed for suspected melanoma did not harbor a melanoma.2 In the 1970s, when Zimmerman et al3 and Zimmerman and McLean4 proposed that enucleation increased mortality by promoting micrometastases during surgery, the desirability of prompt enucleation was seriously questioned. About this same time, several investigators began to experiment with so-called conservative forms of treatment that allowed the patient with a melanoma to retain the affected eye. While conservative management includes radiation, photocoagulation, and eye wall resection, among others, radiation therapy has been evaluated most extensively.

See also pp 916 and 924.

The two types of radiation treatment are brachytherapy

First Page Preview View Large
First page PDF preview
First page PDF preview
×